Search results

Source:

GOV UK (Remove filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 24 March 2021

A summary of letters and drug alerts recently sent to healthcare professionals.

Read Summary

Type:

Safety Alerts (Add filter)

Source:

GOV UK (Remove filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 24 March 2021

Periodically perform skin examinations in patients on bendamustine-containing regimens and consider PML in the differential diagnosis for patients on bendamustine with new or worsening neurological, ...

Read Summary

Type:

Safety Alerts (Add filter)

Source:

GOV UK (Remove filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 24 March 2021

A summary of advice recently issued by the MHRA relating to coronavirus (COVID-19), up to 18 March 2021.

Read Summary

Type:

Safety Alerts (Add filter)

Source:

GOV UK (Remove filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 18 February 2021

The indication of ulipristal acetate 5mg for uterine fibroids has been further restricted due to the risk of serious liver injury and liver failure, with some cases requiring liver transplantation.

Read Summary

Type:

Safety Alerts (Add filter)

Source:

GOV UK (Remove filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 18 February 2021

Pregabalin has been associated with infrequent reports of severe respiratory depression, including some cases without the presence of concomitant opioid medicines. Patients with compromised...

Read Summary

Type:

Safety Alerts (Add filter)

Source:

GOV UK (Remove filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 18 February 2021

Information on the newly launched Safer Medicines in Pregnancy and Breastfeeding Consortium and a new report on optimising data on medicines used during pregnancy.

Read Summary

Type:

Safety Alerts (Add filter)

Source:

GOV UK (Remove filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 18 February 2021

When children receiving replacement therapy for adrenal insufficiency are being switched from hydrocortisone tablets to Alkindi granules, parents or carers should be informed of the need to be extra...

Read Summary

Type:

Safety Alerts (Add filter)

Source:

GOV UK (Remove filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 18 February 2021

A summary of letters and drug alerts recently sent to healthcare professionals.

Read Summary

Type:

Safety Alerts (Add filter)

Source:

GOV UK (Remove filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 18 February 2021

A summary of advice recently issued by the MHRA relating to coronavirus (COVID-19), up to 16 February 2021.

Read Summary

Type:

Safety Alerts (Add filter)

Source:

GOV UK (Remove filter)

Source:

Medicines and Healthcare products Regulatory Agency - MHRA (Remove filter)

Published by Medicines and Healthcare products Regulatory Agency, 07 January 2021

SSRIs and SNRIs are known to increase bleeding risks due to their effect on platelet function. Data from observational studies suggest that the use of SSRI/SNRI antidepressants during the month...

Read Summary

Type:

Safety Alerts (Add filter)